Skye Bioscience, Inc. (SKYE)
Last updated: 2026-10-22 21:17:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Skye Bioscience, Inc. (SKYE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.59, with a market capitalization of $7.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.50 to $13.28. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$7.17M | |
$1.65 | |
$29,000.00 | |
$1.50 | |
$1.63 | |
23.37K | |
91.58K | |
-- | |
$13.28 | |
$1.50 | |
-- | |
-- |
Skye Bioscience, Inc. (SKYE) After-Hours Stock Price
Skye Bioscience, Inc. (SKYE) is trading at $1.60 in after-hours trading as of 2026-10-22 21:01:00, down 1.84% ($0.03) from the regular-session close of $1.63.
After-hours trading shows how investors are pricing SKYE after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Skye Bioscience, Inc. (SKYE) 7-Day Stock Price Change
Over the past seven days, Skye Bioscience, Inc. (SKYE) moved from $1.53 to $1.59, representing a gain of 4.05% ($0.06).
The stock traded between $1.50 and $1.66 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 21.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
SKYE 52-Week Price Position
Position in Range: 0.8%
SKYE is currently trading at $1.59, placing it 0.8% of the way from its 52-week low of $1.50 to its 52-week high of $13.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Skye Bioscience, Inc. (SKYE)?
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Skye Bioscience, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Skye Bioscience, Inc. (SKYE) Stock on MEXC
Eligible investors can buy real shares of Skye Bioscience, Inc. (SKYE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Skye Bioscience, Inc. (SKYE) stock price today?
2.Is SKYE stock going up or down today?
3.What is SKYE pre-market price?
4.What is SKYE after-hours price?
5.Is SKYE stock trading now?
6.Where does SKYE sit relative to its 52-week high and low?
7.What sector is Skye Bioscience, Inc. in?
8.What is Skye Bioscience, Inc.'s market capitalization and where is it listed?
9.How is SKYE valued in terms of P/E ratio and EPS?
10.Does Skye Bioscience, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
SKYE Stock Calculator
Estimate the value between SKYE shares and USD.
SKYE Shares to USD
1.00 SKYE shares = 1.592 USD
Calculations are estimates based on the latest available price and are for reference only.



